Latest Pharma and Biotech News
Biotechnology
3 September 2026 South Korean biotech Alteogen revealed it has entered into an option and license agreement with Swiss pharma giant Novartis for the development and commercialization of subcutaneous (SC) products utilizing ALT-B4 powered by Alteogen's Hybrozyme technology.
Today's issue
Refine search
Pharmaceutical
An Expert View from Ethan Smith, Director of Oncology, Norstella. 3 September 2026
Biotechnology
Japan’s Ono Pharmaceutical has entered into a drug discovery partnership agreement with US biotech Aitia, whose causal AI-powered Gemini Digital Twin Platform uncovers disease biology and knowledge. 3 September 2026
Biotechnology
US pharma major AbbVie announced positive top-line results from the Phase III CERVINO trial evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, against investigator's choice of standard available therapies (SAT) in triple-class exposed relapsed/refractory multiple myeloma (RRMM). 3 September 2026
Biotechnology
Philadelphia, USA-based Medicus Pharma has entered into a co-development and license agreement with US pharma giant Pfizer. 3 September 2026
Biotechnology
Priothera, a late-stage clinical biopharmaceutical company, has announced the appointment of Dr Nigel Clark, as chief business officer (CBO). 3 September 2026
Biotechnology
Italian biotech Resalis Therapeutics has appointed Diana Røpcke as chief medical officer (CMO). 3 September 2026
Biotechnology
Shares of Chinese biopharma Hutchmed leapt 15.3% to HK$22.06 after it announced an exclusive development and license agreement with a subsidiary of GSK, granting worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. 3 September 2026
Pharmaceutical
Franco-American AI firm Owkin has signed a licensing agreement with Boehringer Ingelheim. 3 September 2026
Biotechnology
South Korean biotech Alteogen revealed it has entered into an option and license agreement with Swiss pharma giant Novartis for the development and commercialization of subcutaneous (SC) products utilizing ALT-B4 powered by Alteogen's Hybrozyme technology. 3 September 2026
Biotechnology
Japanese pharma major Eisai and US biotech Biogen said China's National Medical Products Administration (NMPA) has approved the subcutaneous autoinjector formulation of Leqembi (lecanemab) as an initiation treatment for mild cognitive impairment or mild dementia due to Alzheimer's disease, collectively termed early Alzheimer's disease. 3 September 2026
Pharmaceutical
America’s strong intellectual property (IP) system provides the certainty needed to invest in the risky and costly process of developing new medicines, noted trade group Pharmaceutical Research and Manufacturers of America (PhRMA) in a website posting. 3 September 2026
Biotechnology
Dutch gene therapy company uniQure has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington’s disease. 3 September 2026
Pharmaceutical
The US Food and Drug Administration (FDA) publishes almost every stage of its manufacturing enforcement process, from inspection outcomes to the letters themselves. The databases are free, searchable and updated continuously. Read together, they show an agency that keeps finding the same small set of faults, in places that do not always match assumptions. 3 September 2026
Biotechnology
USA-based biotech company Typewriter Therapeutics, which also runs a Japanese arm, came out of stealth on Wednesday with $56 million in series A financing. The round was led by US venture firm AN Venture Partners and US investment firm RA Capital Management, with Japanese venture firm ANRI, Gemseki and SBI US Gateway Fund also taking part. 3 September 2026
Pharmaceutical
USA-based rare disease specialist Ultragenyx Pharmaceutical has reported that apazunersen (GTX-102) failed to separate from control on either of the two main measures in the Phase III Aspire study in Angelman syndrome, ending the first late-stage test of an antisense drug in the genetic disorder. 3 September 2026
Biotechnology
Connecticut-based Invivyd, a biopharma focused on protection from serious viral infectious diseases, has appointed Marc Elia, current chairman of its board, as chief executive. 3 September 2026
Biosimilars
South Korea’s Samsung Bioepis today announced the marketing approval of Ustekinumab BS Intravenous Infusion 130mg (NIPRO), a biosimilar referencing Johnson & Johnson’s Stelara (ustekinumab), indicated for an induction therapy for moderate-to-severe active Crohn’s disease where other treatments are ineffective. 3 September 2026
Biotechnology
Privately-held US biotech Treeline Biosciences today announced a clinical trial collaboration and supply agreement with Swiss giant Roche to evaluate TLN-121, Treeline's BCL6 degrader. 2 September 2026
Pharmaceutical
August was dominated by a wave of large radiopharmaceutical and rare disease consolidation. 2 September 2026
Pharmaceutical
The USA's Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to build the equipment needed to make individualized RNA medicines close to the patient, awarding contracts worth up to $125 million in research and development funding. 2 September 2026
All news
Pharmaceutical
An Expert View from Ethan Smith, Director of Oncology, Norstella. 3 September 2026
Biotechnology
Japan’s Ono Pharmaceutical has entered into a drug discovery partnership agreement with US biotech Aitia, whose causal AI-powered Gemini Digital Twin Platform uncovers disease biology and knowledge. 3 September 2026
Biotechnology
US pharma major AbbVie announced positive top-line results from the Phase III CERVINO trial evaluating etentamig, an investigational BCMA x CD3 bispecific T-cell engager, against investigator's choice of standard available therapies (SAT) in triple-class exposed relapsed/refractory multiple myeloma (RRMM). 3 September 2026
Biotechnology
Philadelphia, USA-based Medicus Pharma has entered into a co-development and license agreement with US pharma giant Pfizer. 3 September 2026
Biotechnology
Priothera, a late-stage clinical biopharmaceutical company, has announced the appointment of Dr Nigel Clark, as chief business officer (CBO). 3 September 2026
Biotechnology
Italian biotech Resalis Therapeutics has appointed Diana Røpcke as chief medical officer (CMO). 3 September 2026
Biotechnology
Shares of Chinese biopharma Hutchmed leapt 15.3% to HK$22.06 after it announced an exclusive development and license agreement with a subsidiary of GSK, granting worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. 3 September 2026
Pharmaceutical
Franco-American AI firm Owkin has signed a licensing agreement with Boehringer Ingelheim. 3 September 2026
Biotechnology
South Korean biotech Alteogen revealed it has entered into an option and license agreement with Swiss pharma giant Novartis for the development and commercialization of subcutaneous (SC) products utilizing ALT-B4 powered by Alteogen's Hybrozyme technology. 3 September 2026
Biotechnology
Japanese pharma major Eisai and US biotech Biogen said China's National Medical Products Administration (NMPA) has approved the subcutaneous autoinjector formulation of Leqembi (lecanemab) as an initiation treatment for mild cognitive impairment or mild dementia due to Alzheimer's disease, collectively termed early Alzheimer's disease. 3 September 2026
Pharmaceutical
America’s strong intellectual property (IP) system provides the certainty needed to invest in the risky and costly process of developing new medicines, noted trade group Pharmaceutical Research and Manufacturers of America (PhRMA) in a website posting. 3 September 2026
Biotechnology
Dutch gene therapy company uniQure has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval of ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for the treatment of Huntington’s disease. 3 September 2026
Pharmaceutical
The US Food and Drug Administration (FDA) publishes almost every stage of its manufacturing enforcement process, from inspection outcomes to the letters themselves. The databases are free, searchable and updated continuously. Read together, they show an agency that keeps finding the same small set of faults, in places that do not always match assumptions. 3 September 2026
Biotechnology
USA-based biotech company Typewriter Therapeutics, which also runs a Japanese arm, came out of stealth on Wednesday with $56 million in series A financing. The round was led by US venture firm AN Venture Partners and US investment firm RA Capital Management, with Japanese venture firm ANRI, Gemseki and SBI US Gateway Fund also taking part. 3 September 2026
Pharmaceutical
USA-based rare disease specialist Ultragenyx Pharmaceutical has reported that apazunersen (GTX-102) failed to separate from control on either of the two main measures in the Phase III Aspire study in Angelman syndrome, ending the first late-stage test of an antisense drug in the genetic disorder. 3 September 2026
Biotechnology
Connecticut-based Invivyd, a biopharma focused on protection from serious viral infectious diseases, has appointed Marc Elia, current chairman of its board, as chief executive. 3 September 2026
Biosimilars
South Korea’s Samsung Bioepis today announced the marketing approval of Ustekinumab BS Intravenous Infusion 130mg (NIPRO), a biosimilar referencing Johnson & Johnson’s Stelara (ustekinumab), indicated for an induction therapy for moderate-to-severe active Crohn’s disease where other treatments are ineffective. 3 September 2026
Biotechnology
Privately-held US biotech Treeline Biosciences today announced a clinical trial collaboration and supply agreement with Swiss giant Roche to evaluate TLN-121, Treeline's BCL6 degrader. 2 September 2026
Pharmaceutical
August was dominated by a wave of large radiopharmaceutical and rare disease consolidation. 2 September 2026
Pharmaceutical
The USA's Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to build the equipment needed to make individualized RNA medicines close to the patient, awarding contracts worth up to $125 million in research and development funding. 2 September 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze